Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Alkermes Ups Bid for Avadel to $2.37 Billion After Rival Offer | Contract Pharma

What are you searching for?

Sign in
Breaking News

Alkermes Ups Bid for Avadel to $2.37 Billion After Rival Offer

The transaction is expected to close in the first quarter of 2026.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Alkermes PLC has raised its offer to acquire Avadel Pharmaceuticals PLC to as much as $22.50 a share, valuing the deal at about $2.37 billion. The revised terms include $21 in cash and a contingent value right worth up to $1.50 a share, tied to U.S. Food and Drug Administration approval of Avadel’s LUMRYZ treatment for idiopathic hypersomnia by the end of 2028.

The companies signed an amended agreement on Nov. 18, following Avadel’s disclosure last week of an unsolicited bid from Denmark’s H. Lundbeck A/S. Avadel’s board initially deemed Lundbeck’s proposal superior but reversed course after reviewing Alkermes’ revised offer, citing stronger CVR terms and a higher likelihood of payout.

Both boards have approved the amended deal, which is expected to close in the first quarter of 2026, subject to customary conditions. The cash component of Alkermes’ offer matches Lundbeck’s bid, but Avadel said the CVR in Alkermes’ proposal offers better prospects than Lundbeck’s, which was considered unlikely to be achieved.

The move underscores intensifying competition in the sleep-disorder treatment market, where LUMRYZ is seen as a key growth driver.

Other Pharma Industry Acquisitions

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics